Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs

NCT07436494 | Completed

• 1 other identifier: 2026-Rheumatology-2
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The COVID-19 pandemic has caused significant psychological distress among patients with chronic diseases. Individuals receiving immunosuppressive therapies may experience increased anxiety due to perceived vulnerability to infection. This observational study aims to compare coronavirus-related anxiety levels in patients using biologic disease-modifying antirheumatic drugs (bDMARDs) and those using conventional disease-modifying antirheumatic drugs (cDMARDs). Adult patients followed at the rheumatology outpatient clinic were contacted by telephone. After verbal consent was obtained, participants completed a patient information form and the Coronavirus Anxiety Scale. Anxiety levels and pandemic-related experiences were compared between treatment groups.

Conditions

COVID-19; Anxiety; Rheumatic Diseases

Keywords

Biologic DMARD; Conventional DMARD; Coronavirus Anxiety Scale; Rheumatology; Pandemic

Outcome Measures

Primary Outcomes (1)

• Coronavirus Anxiety Scale Score

  Anxiety level measured using the validated Coronavirus Anxiety Scale (CAS). The total score ranges from 0 to 20, with higher scores indicating greater coronavirus-related anxiety.

  Baseline

Study Arms (2)

Biologic DMARD group (bDMARD)

Adult rheumatology patients receiving biologic disease-modifying antirheumatic drugs

Other: Current treatment (no intervention assigned)

Conventional DMARD group (cDMARD)

Adult rheumatology patients receiving conventional disease-modifying antirheumatic drugs

Other: Current treatment (no intervention assigned)

Interventions

Current treatment (no intervention assigned) OTHER

Participants are grouped based on their current prescribed DMARD regimen; no study intervention is administered.

Biologic DMARD group (bDMARD); Conventional DMARD group (cDMARD)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with established rheumatic diseases under treatment with biologic or conventional DMARD therapy who were actively followed at a tertiary care rheumatology outpatient clinic during the COVID-19 pandemic.

You may qualify if:

• Age ≥18 years
• Diagnosis of rheumatic disease
• Currently receiving biologic or conventional disease-modifying antirheumatic drugs (DMARDs)
• Followed at the rheumatology outpatient clinic during the COVID-19 pandemic period
• Provided verbal informed consent

You may not qualify if:

• Age \<18 years
• Inability to complete telephone interview
• Cognitive impairment preventing reliable questionnaire response
• Refusal to participate

Sponsors & Collaborators

• Bursa City Hospital: lead

Study Sites (1)

Bursa City Hospital

Bursa, Türkiye, 16600, Turkey (Türkiye)

Location

MeSH Terms

Conditions

COVID-19; Anxiety Disorders; Rheumatic Diseases

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Mental Disorders; Musculoskeletal Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 12, 2026
• First Posted: February 27, 2026
• Study Start: October 15, 2020
• Primary Completion: January 15, 2021
• Study Completion: January 25, 2021
• Last Updated: February 27, 2026

Record last verified: 2026-02

Locations

TU (1)